Atezolizumab ESMO 2016: OAK Trial Results in Non-Small Cell Lung Cancer

At the European Society for Medical Oncology (ESMO) 2016 Congress, Dr. Fabrice Barlesi from Aix-Marseille University presented the groundbreaking results of the Phase 3 OAK trial. This study compared Atezolizumab (Tecentriq), an anti-PD-L1 antibody, with Docetaxel (standard chemotherapy) in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who had previously received platinum-based chemotherapy.

Study Design: OAK Phase 3 Trial

The OAK trial enrolled 1,225 patients with metastatic NSCLC who had failed one or two prior lines of systemic therapy. Participants were randomized 1:1 to receive either:

1. Atezolizumab: 1,200 mg intravenously every three weeks.
2. Docetaxel: 75 mg/m² intravenously every three weeks.

The primary endpoint was overall survival (OS).

Key Survival Findings

With a median follow-up of 19 months, the trial achieved its primary goal:

• Median OS: 13.8 months for Atezolizumab vs. 9.6 months for Docetaxel—a survival benefit of approximately 4 months.
• 12-Month OS Rate: 55% (Atezolizumab) vs. 41% (Docetaxel).
• 18-Month OS Rate: 40% (Atezolizumab) vs. 27% (Docetaxel).

Impact of PD-L1 Expression

The benefit of Atezolizumab was observed regardless of PD-L1 expression levels:

• PD-L1 Negative (TC0/IC0): Median OS was 12.6 months for Atezolizumab vs. 8.9 months for Docetaxel.
• High PD-L1 Expression (TC3/IC3): Median OS significantly extended to 20.5 months with Atezolizumab vs. 8.9 months with Docetaxel.

Safety and Durability

Atezolizumab demonstrated a more favorable safety profile compared to Docetaxel. Adverse events reported in the Atezolizumab group included pneumonitis (1%), hepatitis (0.3%), and colitis (0.3%). Notably, 20.5% of patients in the Atezolizumab group remained on treatment for more than 12 months, indicating a durable response for many participants.

Conclusion

The OAK trial results established Atezolizumab as a potent second-line treatment option for NSCLC, offering superior survival and better tolerability than standard Docetaxel chemotherapy, independent of the patient's PD-L1 status.

#LungCancer #NSCLC #Atezolizumab #Tecentriq #ESMO2016 #OAKTrial #Immunotherapy

Figure 1

Figure 2

Figure 3

Figure 4